Towards the eradication of HPV infection through universal specific vaccination
详细信息    查看全文
  • 作者：Piergiorgio Crosignani (1)
    Antonella De Stefani (2)
    Gaetano Maria Fara (3)
    Andrea M Isidori (4)
    Andrea Lenzi (5)
    Carlo Antonio Liverani (6)
    Alberto Lombardi (7)
    Francesco Saverio Mennini (10) (8) (9)
    Giorgio Palu-/a> (11)
    Sergio Pecorelli (12)
    Andrea P Peracino (13) (7)
    Carlo Signorelli (14)
    Gian Vincenzo Zuccotti (15)
  • 关键词：HPV infection ; Condylomas ; Cervical cancer ; Genital cancer ; Oro ; pharyngeal cancer ; Anti ; HPV vaccines ; Universal vaccination ; Vaccination programs ; Incremental cost ; effectiveness ratio
  • 刊名：BMC Public Health
  • 出版年：2013
  • 出版时间：December 2013
  • 年：2013
  • 卷：13
  • 期：1
  • 全文大小：242KB
  • 参考文献：1. Baseman JG, Koutsky LA: The epidemiology of human papilloma virus infections. / J Clin Virol 2005,32(Suppl 1):S16-S24.
    2. Kahn JA, Burk RD: Papillomavirus vaccines in perspective. / Lancet 2007, 369:2135-137.
    3. Bruni L, Diaz M, Castellsagué X, Ferrer E, Bosch FX, de Sanjosé S: Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. / J Infect Dis 2010,202(12):1789-799.
    4. Syrjanen KJ: Annual disease burden due to human papillomavirus 16 and 18 infections in Finland. / Scand J Infect Dis Suppl 2009, 108:2-2.
    5. Zur Hausen H, de Villiers EM, Gissmann L: Papillomavirus infections and human genital cancer. / Gynecol Oncol 1981, 12:S124-S128.
    6. Zur Hausen H: The search for infectious causes of human cancers where and why. / Virology 2009,392(1):1-0.
    7. Tota J, Chevarie-Davis M, Richardson LA, Devries M, Franco EL: Epidemiology and burden of HPV infection and related diseases: implications for prevention strategies. / Prev Med 2011, 53:S12-S21.
    8. Genden EM, Sambur IM, de Almeida JR, Posner M, Rinaldo A, Rodrigo JP, Strojan P, Takes RP, Ferlito A: Human papillomavirus and oropharyngeal squamous cell carcinoma: what the clinician should know. / Eur Arch Otorhinolaryngol 2013,270(2):405-16.
    9. LaCour DE, Trimble C: Human papillomavirus in infants: transmission, prevalence, and persistence. / J Pediatr Adolesc Gynecol 2012, 25:93-7.
    10. Unger ER, Fajman NN, Maloney EM, Onyekwuluje J, Swan DC, Howard L, Beck-Sague CM, Sawyer MK, Girardet RG, Sautter RL, Hammerschlag MR, Black CM: Anogenital human papillomavirus in sexually abused and non abused children: a multicenter study. / Pediatrics 2011,128(3):e658-e665.
    11. Jones V, Smith SJ, Omar HA: Nonsexual transmission of anogenital warts in children: a retrospective analysis. / ScientificWorldJournal 2007, 7:1896-899.
    12. Honor G: Ano-genital in children: sexual abuse or not? / J Pediatr Health Care 2004,18(4):165-70.
    13. Fairley CK, Gay NJ, Forbes A, Abramson M, Garland SM: Hand-genital transmission of genital warts? An analysis of prevalence data. / Epidemiol Infect 1995, 115:169-76.
    14. Sonnex C, Strauss S, Gray JJ: Detection of human papillomavirus DNA on the fingers of patients with genital warts. / Sex Transm Inf 1999, 75:317-19.
    15. Rachel L, Winer RL, Hughes JP, Feng Q, Fu Xi L, Cherne S, O’Reilly S, Kiviat NB, Koutsky LA: Detection of genital HPV types in fingertip samples from newly sexually active female university students. / Cancer Epidemiol Biomarkers Prev 2010,19(7):1682-685.
    16. Brotherton JM, Fridman M, May CL, Chappell G, Saville AM, Gertig DM: Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. / Lancet 2011, 377:2085-092.
    17. Ali H, Donovan B, Wand H, Read TRH, Regan DG, Grulich AE, Fairley CK, Guy RJ: Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. / BMJ 2013, 346:f2032. doi:10.1136/bmj.f2032. Published 19 April 2013
    18. Morbidity and Mortality Weekly Reports / MMWR 2012,61(No.15):258-61. http://www.cdc.gov/mmwr/pdf/wk/mm6115.pdf
    19. Hartwig S, Syrjanen S, Dominiak-Felden G, Brotons M, Castellsaguè X: Estimation of the epidemiological burden of human papillomavirus-related cancers and non-malignant diseases in men in Europe: a review. / BMC Cancer 2012, 12:30.
    20. Gravitt PE: The known unknowns of HPV natural history. / J Clin Invest 2011,121(12):4593-599.
    21. Frazer IH: Prevention of cervical cancer through papillomavirus vaccination. / Nature Rev Immunol 2004, 4:46-5.
    22. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S: Human papillomavirus and cervical cancer. / Lancet 2007,370(9590):890-07.
    23. Frazer IH: Measuring serum antibody to human papillomavirus following infection or vaccination. / Gynecol Oncol 2010,118(Issue 1, Supplement 1):S8-S11.
    24. Franco E, Villa LL, Sobrinho JP, Prado JM, Rousseau MC, Desy M, Rohan TE: Epidemiology and natural history of human papillomavirus infection in women from a high-risk area of cervical cancer. / J Infect Dis 1999,80(5):1415-423.
    25. Woodman CB, Collins S, Winter H, Bailey A, Ellis J, Prior P, Yates M, Rollason TP, Young LS: Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. / Lancet 2001,357(9271):1831-836.
    26. Goldstein MA, Goodman A, del Carmen MG, Wilbur DC: Case records of the Massachusetts General Hospital. Case 10-009. A 23-year-old woman with an abnormal Papanicolaou smear. / NEJM 2009,360(13):1337-344.
    27. Giuliano AR, Tortelero-Luna G, Ferrer E, Burchell AN, de Sanjose S, Kjaer SK, Munoz N, Schiffman M, Bosch FX: Epidemiology of human papilloma virus infection in men, cancers other than cervical and benign conditions. / Vaccine 2008,26(Suppl 10):K17-K28.
    28. Monk BJ, Tewari KS: The spectrum and clinical sequelae of human papillomavirus infection. / Nov Gynecol Oncol 2007,107(2 Suppl 1):S6-S13.
    29. Badaracco G, Rizzo C, Mafera B, Pichi B, Giannarelli D, Rahimi SS, Vigili MG, Venuti A: Molecular analyses and prognostic relevance of HPV in head and neck tumours. / Oncol Rep 2007, 17:931-39.
    30. Klussmann JP, Weissenborn SJ, Wieland U, Dries V, Kolligs J, Jungehuelsing M, Eckel HE, Dienes HP, Pfister H, Fuchs PG: Prevalence, distribution, and viral load of human papillomavirus 16 DNA in tonsillar carcinomas. / Cancer 2001, 92:2875-884.
    31. De Stefani A, Boffano P, Averono G, Ramella A, Pia F, Bongioannini G: Prevalence and characteristics of HPV infection in oropharyngeal cancer. / J Craniofac Surg 2013,24(1):e40-e43.
    32. Herfs M, Hubert P, Moutschen M, Delvenne P: Mucosal junctions: open doors for HPV and HIV infections? / Trends Microbiol 2011, 19:114-20.
    33. Giuliano AR, Lazcano-Ponce E, Villa LL, Flores R, Salmeron J, Lee JH, Papenfuss MR, Abrahamsen M, Jolles E, Nielson CM, Baggio ML, Silva R, Quiterio M: The human papillomavirus infection in Men (HIM) study: HPV prevalence and type-distribution among men residing in Brazil, Mexico, and the US. / Cancer Epidemiol Biomarkers Prev 2008,17(8):2036-043.
    34. Vardas E, Giuliano AR, Goldstone S, Palefsky JM, Moreira ED Jr, Penny ME, Aranda C, Jessen H, Moi H, Ferris DG, Liaw KL, Marshall JB, Vuocolo S, Barr E, Haupt RM, Garner EI, Guris D: External genital human papillomavirus prevalence and associated factors among heterosexual men on 5 continents. / J Infect Dis 2011, 203:58-5.
    35. Marks M, Gravitt PE, Gupta SB, Liaw KL, Kim E, Tadesse A, Phongnarisorn C, Wootipoom V, Yuenyao P, Vipupinyo C, Rugpao S, Sriplienchan S, Celentano DD: The association of hormonal contraceptive use and HPV prevalence. / Int J Cancer 2011,128(12):2962-970.
    36. Smith E, Rubenstein LM, Haugen TH, Hamsikova E, Turek LP: Tobacco and alcohol use increase the risk of both HPV associated and HPV independent head and neck cancers. / Cancer Causes Control 2010, 21:1369-378.
    37. Winer RL, Hughes JP, Feng Q, O’Reilly S, Kiviat NB, Holmes KK, Koutsky LA: Condom use and the risk of genital human papillomavirus infection in young women. / NEJM 2006,354(25):2645-654.
    38. Wawer MJ, Tobian AA, Kigozi G, Kong X, Gravitt PE, Serwadda D, Nalugoda F, Makumbi F, Ssempiija V, Sewankambo N, Watya S, Eaton KP, Oliver AE, Chen MZ, Reynolds SJ, Quinn TC, Gray RH: Effect of circumcision of HIV-negative men on transmission of human papillomavirus to HIV-negative women: a randomised trial in Rakai. / Uganda. Lancet 2011,377(9761):209-18.
    39. Tobian AA, Serwadda D, Quinn TC, Kigozi G, Gravitt PE, Laeyendecker O, Charvat B, Ssempijja V, Riedesel M, Oliver AE, Nowak RG, Moulton LH, Chen MZ, Reynolds SJ, Wawer MJ, Gray RH: Male circumcision for the prevention of HSV-2 and HPV infections and syphilis. / NEJM 2009,360(13):1298-309.
    40. Smith JS, Melendy A, Rana RK, Pimenta JM: Age-specific prevalence of infection with human papillomavirus in females: a global review. / J Adolesc Health 2008, 43:S5-S25.
    41. Giuliano AR, Lee JH, Fulp W, Villa LL, Lazcano E, Papenfuss MR, Abrahamsen M, Salmeron J, Anic GM, Rollison DE, Smith D: Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study. / Lancet 2011, 377:932-40.
    42. Smith JS, Gilbert PA, Melendy A, Rana RK, Pimenta JM: Age-specific prevalence of human papilloma virus infection in males: a global review. / J Adolesc Health 2011, 48:540-52.
    43. Greer CE, Wheeler CM, Ladner MB, Beutner K, Coyne MY, Liang H, Langenberg A, Yen TS, Ralston R: Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts. / J Clin Microbiol 1995,33(8):2058-063.
    44. Blomberg M, Friis S, Munk C, Bautz A, Kjaer SK: Genital warts and risk of cancer-a Danish study of nearly 50,000 patients with genital warts. / J Infect Dis 2012,205(10):1544-553.
    45. Grulich AE, Jin F, Conway EL, Stein AN, Hocking J: Cancers attributable to human papillomavirus infection. / Sex Health 2010, 7:244-52.
    46. / WHO/ICO Information Centre, Human Papillomavirus and Related Cancers. Summary Report Update. EUROPE; 2010. [ / Summary Report Update] http://www.who.int/hpvcentre
    47. Baio GL, Capone A, Marcellusi A, Mennini FS, Favato G: Economic burden of human papillomavirus-related diseases in Italy. / PLoS One 2012,7(11):e49699.
    48. Vajdic CM, van Leeuwen MT, Jin F, Prestage G, Medley G, Hillman RJ, Stevens MP, Botes LP, Zablotska I, Tabrizi SN, Grulich AE: Anal human papillomavirus genotype diversity and co-infection in a community-based sample of homosexual men. / Sex Transm Infect 2009, 85:330-35.
    49. Chin-Hong PV, Vittinghoff E, Cranston RD, Buchbinder S, Cohen D, Colfax G, Da Costa M, Darragh T, Hess E, Judson F, Koblin B, Madison M, Palefsky JM: Age-specific prevalence of anal human papillomavirus infection in HIV-negative sexually active men who have sex with men: the EXPLORE study. / J Infect Dis 2004, 190:2070-076.
    50. Van der Snoek EM, Niesters HG, Mulder PG, van Doornum GJ, Osterhaus AD, van der Meijden WI: Human papillomavirus infection in men who have sex with men participating in a Dutch gay-cohort study. / Sex Transm Dis 2003, 30:639-44.
    51. Daling JR, Weiss NS, Hislop TG, Maden C, Coates RJ, Sherman KJ, Ashley RL, Beagrie M, Ryan JA, Corey L: Sexual practices, sexually transmitted diseases, and the incidence of anal cancer. / NEJM 1987, 317:973-77.
    52. Daling JR, Weiss NS, Klopfenstein LL, Cochran LE, Chow WH, Daifuku R: Correlates of homosexual behavior and the incidence of anal cancer. / JAMA 1982, 247:1988-990.
    53. Pirotta M, Stein AN, Conway EL, Harrison C, Britt H, Garland S: Genital warts incidence and healthcare resource utilisation in Australia. / Sex Transm Infect 2010, 86:181-86.
    54. / Cervarix: Summary of Product Characteristics. http://www.medicines.org.uk/emc/medicine/20204/SPC/Cervarix
    55. / Gardasil: Summary of Product Characteristics. http://www.medicines.org.uk/emc/medicine/19016/SPC/gardasil/
    56. Giuliano AR, Palefsky JM, Goldstone S, Moreira ED Jr, Penny ME, Aranda C, Vardas E, Moi H, Jessen H, Hillman R, Chang YH, Ferris D, Rouleau D, Bryan J, Marshall JB, Vuocolo S, Barr E, Radley D, Haupt RM, Guris D: Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. / NEJM 2011,364(5):401-11.
    57. Palefsky J, Giuliano AR, Goldstone S, Moreira ED Jr, Aranda C, Jessen H, Hillman R, Ferris D, Coutlee F, Stoler MH, Marshall JB, Radley D, Vuocolo S, Haupt RM, Guris D, Garner EI: HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. / NEJM 2011, 365:1576-585.
    58. Goldstone S: A case assignment methodology for determining quadrivalent HPV vaccine efficacy against AIN in men having sex with men. In / 26th International Papillomavirus Conference. Montreal, Canada; 2010. http://www.eurogin.com/2010/EUROGIN2010_Abstracts.pdf
    59. Lu B, Lu B, Kumar A, Castellsagué X, Giuliano AR: Efficacy and safety of prophylactic vaccines against cervical HPV infection and disease among women: a systematic review & meta-analysis. / BMC Infect Dis 2011, 11:13.
    60. Rowhani-Rahbar A, Alvarez FB, Bryan JT, Hughes JP, Hawes SE, Weiss NS, Koutsky LA: Evidence of immune memory 8,5 years following administration of a prophylactic human papillomavirus type 16 vaccine. / J Clin Virol 2012,53(3):239-43.
    61. Kjaer SK: An evaluation of the Long-term effectiveness, immunogenicity and safety of Gardasil? / EUROGIN 2011. http://www.eurogin.com/2011/Eurogin-2011-Abstracts.pdf
    62. Romanowski B, de Borba PC, Naud PS, Roteli-Martins CM, De Carvalho NS, Teixeira JC, Aoki F, Ramjattan B, Shier RM, Somani R, Barbier S, Blatter MM, Chambers C, Ferris D, Gall SA, Guerra FA, Harper DM, Hedrick JA, Henry DC, Korn AP, Kroll R, Moscicki AB, Rosenfeld WD, Sullivan BJ, Thoming CS, Tyring SK, Wheeler CM, Dubin G, Schuind A, Zahaf T, Greenacre M, Sgriobhadair A, GlaxoSmithKline Vaccine HPV-007 Study Group: Sustained efficacy and immunogenicity of the human papillomavirus (HPV)- 16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. / Lancet 2009,374(9706):1975-985.
    63. Fraser C, Tomassini JE, Xi L, Golm G, Watson M, Giuliano AR, Barr E, Ault KA: Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine. / Vaccine 2007, 25:4324-333.
    64. Block SL, Nolan T, Sattler C, Barr E, Giacoletti KE, Marchant CD, Castellsagué X, Rusche SA, Lukac S, Bryan JT, Cavanaugh PF Jr, Reisinger KS, Protocol 016 Study Group: Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. / Pediatrics 2006,118(5):2135-145.
    65. Moreira ED Jr, Palefsky JM, Giuliano AR, Goldstone S, Aranda C, Jessen H, Hillman RJ, Ferris D, Coutlee F, Vardas E, Marshall JB, Vuocolo S, Haupt RM, Guris D, Garner EI: Safety and reactogenicity of a quadrivalent human papillomavirus (types 6,11,16,18) L1 viral like particle vaccine in older adolescents and young adults. / Hum Vaccin 2011,7(7):768-75.
    66. Block SL, Brown DR, Chatterjee A, Gold MA, Sings HL, Meibohm A, Dana A, Haupt RM, Barr E, Tamms GM, Zhou H, Reisinger KS: Clinical trial and postlicensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine. / Pediatr Infect Dis J 2010, 29:95-01.
    67. Bonanni P, Cohet C, Kjaer SK, Latham NB, Lambert PH, Reisinger K, Haupt RM: A summary of the post-licensure surveillance initiatives for GARDASIL/SILGARD?. / Vaccine 2010, 28:4719-730.
    68. Oliphant J, Perkins N: Impact of the human papillomavirus vaccine on genital wart diagnoses at Auckland Sexual Health Services. / NZMJ 2011,124(1339):51-8.
    69. Bauer HM, Wright G, Chow J: Evidence of human papillomavirus vaccine effectiveness in reducing genital warts: an analysis of California public family planning administrative claims data, 2007-010. / Am J Public Health 2012,102(5):833-35.
    70. Fairley CK, Hocking JS, Gurrin LC, Chen MY, Donovan B, Bradshaw CS: Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. / Sex Transm Infect 2009,85(7):499-02.
    71. Fairley CK, Donovan B: What can surveillance of genital warts tell us ? / Sex Health 2010,7(3):325-27.
    72. Dorleans F, Giambi C, Dematte L, Cotter S, Stefanoff P, Mereckiene J, O’Flanagan D, Lopalco PL, D’Ancona F, Lévy-Bruhl D, on behalf of the VENICE 2 project gatekeepers group: The current state of introduction of human papillomavirus vaccination into national immunisation schedules in Europe: first results of the VENICE2 2010 survey. / Euro Surveill 2010.,15(47): Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19730
    73. Morbidity and mortality weekly report (MMRW) adult vaccination coverage-United states 2010 2012,61(04):66-2.
    74. Advisory Committee on Immunization Practices (ACIP): Recommendations on the use of quadrivalent human papillomavirus vaccine in males. / MMRW 2011,60(50):1707-708.
    75. Brady MT, Byington CL, Davies HD, Edwards KM, Glode MP, Jackson MA, Keyserling HL, Maldonado YA, Murray DL, Orenstein WA, Schutze GE, Willoughby RE, Zaoutis TE: HPV vaccine recommendations. American academy of paediatrics. / Pediatrics 2012,129(3):602-05.
    76. / Australian Government. Department of Health and Ageing. Immunise Australia Program. Human papillomavirus (HPV). Australian Government. [Accessed 31 July 2011]. [http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/immunise-hpv] [Accessed 31 July 2011]. []
    77. Gertig DM, Brotherton JM, Saville M: Measuring human papillomavirus (HPV) vaccination coverage and the role of the national HPV vaccination program register. / Australia. Sex Health 2011,8(2):171-78.
    78. An Advisory Committee Statement (ACS): National Advisory Committee on Immunization (NACI). Update on Human Papillomavirus (HPV) Vaccines. / Canada Comunicable Disease Report (CCDR) 2012, 37:1-2.
    79. Jit M, Choi YH, Edmunds WJ: Economic evaluation of human papillomavirus vaccination in the United Kingdom. / BMJ 2008, 337:a769. doi:10.1136/bmj.a769.
    80. Kim JJ, Goldie SJ: Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. / BMJ 2009, 339:b3884. doi:10.1136/bmj.b3884.
    81. Taira AV, Neukermans CP, Sanders GD: Evaluating human papillomavirus vaccination programs. / Emerg Infect Dis 2004, 10:1915-923.
    82. Chesson HW, Ekwueme DU, Saraiya M, Markowitz LE: Cost-effectiveness of human papillomavirus vaccination in the United States. / Emerg Infect Dis 2008,14(2):244-51.
    83. Kim JJ, Goldie SJ: Health and economic implications of HPV vaccination in the United States. / NEJM 2008, 359:821-32.
    84. Mennini FS, Giorgi Rossi P, Palazzo F, Largeron N: Health and economic impact associated with a quadrivalent HPV vaccine in Italy. / Gynecol Oncol 2009, 112:370-76.
    85. Elbasha EH, Dasbach EJ, Insinga RP: Model for assessing human papillomavirus vaccination strategies. / Emerg Infect Dis 2007, 13:28-1.
    86. Favato G, Pieri V, Mills R: / Cost-effective analysis of anti-HPV vaccination programme in Italy: a multi-cohort Markov model. 2007. Available at SSRN: http://ssrn.com/abstract=961847 or http://dx.doi.org/10.2139/ssrn.961847
    87. Favato G, Baio G, Capone A, Marcellusi A, Costa S, Garganese G, Picardo M, Drummond M, Jonsson B, Scambia G, Zweifel P, Mennini FS: Novel health economic evaluation of a vaccination strategy to prevent HPV-related diseases. / Med Care 2012,50(12):1076-085.
    88. Rawlins MD, Culyer AJ: National institute for clinical excellence and its value judgments. / BMJ 2004,329(7459):224-27.
    89. Mennini FS, Costa S, Favato G, Picardo M: Anti-HPV vaccination: a review of recent economic data for Italy. / Vaccine 2009, 27:A54-A61.
    90. Nolan TM: The Australian model of immunization advice and vaccine funding. / Vaccine 2010, 28:A76-A83.
    91. Kulasingam S, Connelly L, Conway E, Hocking JS, Myers E, Regan DG, Roder D, Ross J, Wain G: A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian national cervical cancer screening program. / Sex Health 2007, 4:165-75.
    92. Elbasha EH, Dasbach EJ: Impact of vaccinating boys and men against HPV in the United States. / Vaccine 2010, 28:6858-867.
    93. Brisson M, van de Velde N, Franco EL, Drolet M, Boily MC: Incremental impact of adding boys to current human papillomavirus vaccination programs: role of herd immunity. / J Infect Dis 2011,204(3):372-76.
    94. Reece M, Herbenick D, Schick V, Sanders SA, Dodge B, Fortenberry JD: Sexual behaviors, relationships, and perceived health among adult men in the United States: results from a national probability sample. / J Sex Med 2010,7(Suppl 5):291-04.
    95. / ECDC guidance. Introduction of HPV vaccines in European Union countries-an update. http://www.ecdc.europa.eu
    96. Lenzi A, Mirone V, Gentile V, Bartoletti R, Ficarra V, Foresta C, Mariani L, Mazzoli S, Parisi SG, Perino A, Picardo M, Zotti CM: Rome consensus conference - statement; human papilloma virus diseases in males. / BMC Publ Health 2013, 13:117.
    97. Calore EE, Giaccio CM, Nadal SR: Prevalence of anal cytological abnormalities in women with positive cervical cytology. / Diagn Cytopathol 2011,39(5):323-27.
    98. Weiss TW, Zimet GD, Rosenthal SL, Brenneman SK, Klein JD: Human papillomavirus vaccination of males: attitudes and perceptions of physicians who vaccinate females. / J Adolesc Health 2010,47(1):3-1.
    99. Palefsky JM: Human papillomavirus-related disease in men: not just a women’s issue. / J Adolesc Health 2010,46(4 Suppl):S12-S19.
    100. Goldstone SE: Some straight talk about anal human papillomavirus infection. / J Infect Dis 2010,201(10):1450-452.
    101. Oon SF, Winter DC: Perianal condylomas, anal squamous intraepithelial neoplasms and screening: a review of the literature. / J Med Screen 2010,17(1):44-9.
    102. Brewer NT, Ng TW, McRee AL, Reiter PL: Men’s beliefs about HPV-related disease. / J Behav Med 2010, 33:274-81.
    103. Hernandez BY, Wilkens LR, Thompson PJ, Shvetsov YB, Goodman MT, Ning L, Kaopua L: Acceptability of prophylactic human papillomavirus vaccination among adult men. / Hum Vaccine 2010, 6:467-75.
    104. Reiter PL, Brewer NT, McRee AL, Gilbert P, Smith JS: Acceptability of HPV vaccine among a national sample of gay and bisexual men. / Sex Transm Dis 2010, 37:197-03.
    105. Chesson HW, Ekwueme DU, Saraiya M, Dunne EF, Markowitz LE: The cost-effectiveness of male HPV vaccination in the United States. / Vaccine 2011,29(46):8443-450.
    106. Marty R, Roze S, Bresse X, Largeron N, Smith-Palmer J: Estimating the clinical benefits of vaccinating boys and girls against HPV-related diseases in Europe. / BMC Cancer 2013,13(10):1-2.
    107. Baandrup L, Blomberg M, Dehlendorff C, Sand C, Andersen KK, Kjaer SK: Significant decrease in the incidence of genital warts in young Danish women after implementation of a national human papillomavirus vaccination program. / Sex Transm Dis 2013,40(2):130-35.
    108. Grayson M: From an interview to harald Zur Hausen. / Nature 2012,488(7413):16.
    109. Low MI, Attiga YS, Garg G, Schelgal R, Gllicano GI: Can male vaccination reduce burden of human papillomavirus-related disease in the United States? / Viral Immunol 2012,25(3):174-83.
    110. European Centre for Disease Prevention and Control: / Introduction of HPV vaccines in EU countries -an update. Stockholm: ECDC; 2012. doi:10.2900/60814. ISBN 978-2-193-77-
    111. Michels KB, Zur Hausen H: HPV vaccine for all. / Lancet 2009,374(9686):268-70.
    112. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2458/13/642/prepub
  • 作者单位：Piergiorgio Crosignani (1)
    Antonella De Stefani (2)
    Gaetano Maria Fara (3)
    Andrea M Isidori (4)
    Andrea Lenzi (5)
    Carlo Antonio Liverani (6)
    Alberto Lombardi (7)
    Francesco Saverio Mennini (10) (8) (9)
    Giorgio Palu-/a> (11)
    Sergio Pecorelli (12)
    Andrea P Peracino (13) (7)
    Carlo Signorelli (14)
    Gian Vincenzo Zuccotti (15)

    1. Obstetrics and Gynaecology Clinic, Università degli Studi di Milano, Milan, Italy
    2. ENT Department, Ospedale Mauriziano, Turin, Italy
    3. Department of Public Health and Infectious Diseases, Sapienza Università di Roma, Rome, Italy
    4. Department of Experimental Medicine, Sapienza Università di Roma, Rome, Italy
    5. Department of Experimental Medicine, Section of Medical Pathophysiology, Food Science and Endocrinology, Sapienza Università di Roma, Rome, Italy
    6. Preventive Gynecologic Oncology Unit - Department of Mother and Infant Sciences, Università di Milano, Foundation IRCCS Ca-Granda Ospedale Maggiore Policlinico, Milan, Italy
    7. Fondazione Giovanni Lorenzini Medical Science Foundation, Milan, Italy
    10. Institute of Leadership and Management in Healths, Kingston University, London, UK
    8. CEIS Sanità - Centre for Health Economics and Management (CHEM) Faculty of Economics and Faculty of Science, University of Rome “Tor Vergata- Rome, Italy
    9. Faculty of Statistics, University of Rome La Sapienza, Rome, Italy
    11. Department of Molecular Medicine, Università di Padova, Padua, Italy
    12. Department of Mother and Infant Sciences and Biomedical Technologies - Rector, Università di Brescia, Brescia, Italy
    13. Giovanni Lorenzini Medical Science Foundation, Houston, TX, USA
    14. Department SBIBIT, Università di Parma, Parma, Italy
    15. Department of Pediatrics, Università degli Studi di Milano - Luigi Sacco Hospital, Milan, Italy
  • ISSN：1471-2458
文摘
Background The Human Papillomavirus (HPV) is generally recognized to be the direct cause of cervical cancer. The development of effective anti-HPV vaccines, included in the portfolio of recommended vaccinations for any given community, led to the consolidation in many countries of immunization programs to prevent HPV-related cervical cancers. In recent years, increasing evidence in epidemiology and molecular biology have supported the oncogenic role of HPV in the development of other neoplasm including condylomas and penile, anal, vulvar, vaginal, and oro-pharyngeal cancers. Men play a key role in the paradigm of HPV infection: both as patients and as part of the mechanisms of transmission. Data show they are affected almost as often as women. Moreover, no screening procedures for HPV-related disease prevention are applied in men, who fail to undergo routine medical testing by any medical specialist at all. They also do not benefit from government prevention strategies. Discussion A panel of experts convened to focus on scientific, medical, and economic studies, and on the achievements from health organizations-intervention programs on the matter. One of the goals was to discuss on the critical issues emerging from the ongoing global implementation of HPV vaccination. A second goal was to identify contributions which could overcome the barriers that impede or delay effective vaccination programs whose purpose is to eradicate the HPV infection both in women and men. Summary The reviewed studies on the natural history of HPV infection and related diseases in women and men, the increasing experience of HPV vaccination in women, the analysis of clinical effectiveness vs economic efficacy of HPV vaccination, are even more supportive of the economic sustainability of vaccination programs both in women and men. Those achievements address increasing and needed attention to the issue of social equity in healthcare for both genders.

© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号

地址：北京市海淀区学院路29号 邮编：100083

电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700